Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2251 - 2275 of 14977 in total

Pazopanib

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Approved
Matched Description: … It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Isopropamide

Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Approved
Vet approved
Matched Description: … and hypermotility. ... It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity …
Matched Categories: … Alimentary Tract and Metabolism ... isopropamide and psycholeptics …

Venetoclax

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types...
Approved
Investigational
Matched Description: … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Polythiazide

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)
Approved
Matched Description: … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. …
Matched Categories: … polythiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Vosoritide

Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume and in length.[A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions, the...
Approved
Investigational
Matched Description: … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans ... missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and ... [A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lutetium Lu 177 dotatate

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as...
Approved
Investigational
Matched Description: … Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine ... tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver [A31697]. ... The presence of a radioligand allows monitoring of treatment response post therapy and prior to next …
Matched Categories: … Indicators and Reagents ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins …

Pyridostigmine

Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the...
Approved
Investigational
Matched Description: … under various brand and generic names. ... directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and ... By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and …

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … It is composed of two heavy chain molecule fragments and 2 light chain fragments. ... binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and ... olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Rivastigmine

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Approved
Investigational
Matched Description: … Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase …

Ziconotide

Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because...
Approved
Matched Iupac: … 3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosaazatricyclo[40.37.4.2^{21,68}]pentaoctacontan-24-yl]acetic acid …
Matched Description: … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy …
Matched Categories: … Fluids and Secretions ... Calcium-Regulating Hormones and Agents …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and ... [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Investigational
Withdrawn
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Racephedrine

Approved
Experimental
Matched Categories: … Herbs and Natural Products ... Alpha-and Beta-adrenergic Agonists …

Pegademase

Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Approved
Matched Categories: … Enzymes and Coenzymes ... Antineoplastic and Immunomodulating Agents …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and ... [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Fedratinib

Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Approved
Investigational
Matched Description: … -2 and high risk primary and secondary myelofibrosis. ... Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Demecarium

Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase...
Approved
Matched Description: … Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. ... In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Pancrelipase protease

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.[A32742, L2543]...
Approved
Matched Description: … cleave peptide bonds and are involved in food digestion. ... Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and …
Matched Categories: … Enzymes and Coenzymes …

Technetium Tc-99m sulfur colloid

Technetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux. Following injection or oral administration, single...
Approved
Investigational
Matched Description: … studies of esophageal transit and gastroesophageal reflux. ... detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and ... Depending on site of administration and intended usage, Technetium 99m sulfur colloid enters the capillaries …
Matched Categories: … Indicators and Reagents ... Hepatic and Reticulo Endothelial System ... Technetium (99Mtc), Particles and Colloids …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 ... unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an “off-the-shelf ... potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Terizidone

Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
Approved
Investigational
Matched Description: … in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and …
Displaying drugs 2251 - 2275 of 14977 in total